CRF 2 mediates the increased noradrenergic activity in the hypothalamic paraventricular nucleus and the negative state of morphine withdrawal in rats

British Journal of Pharmacology

Volumn 162, Issue 4, 2011, Pages 851-862

  Navarro Zaragoza, Javier ^a   Nãñez, Cristina ^a   Ruiz Medina, Jessica ^b   Laorden, M Luisa ^a   Valverde, Olga ^b   Milanés, M Victoria ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

corticotropin releasing factor 2 receptor; hypothalamic paraventricular nucleus; morphine withdrawal; noradrenergic pathways activity

Indexed keywords

ANTISAUVAGINE 30; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; MORPHINE; NORADRENALIN; PLACEBO; SERINE; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRF RECEPTOR TYPE 2; NERVE PROTEIN; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; HORMONE RESPONSE; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MORPHINE ADDICTION; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; SOLITARY TRACT NUCLEUS; WITHDRAWAL SYNDROME; ANIMAL; DRUG ANTAGONISM; ENZYME ACTIVATION; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; MOLECULARLY TARGETED THERAPY; NERVE CELL; PHOSPHORYLATION; PROTEIN PROCESSING; WISTAR RAT;

ANIMALS; ENZYME ACTIVATION; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; METHOXYHYDROXYPHENYLGLYCOL; MOLECULAR TARGETED THERAPY; MORPHINE DEPENDENCE; NERVE TISSUE PROTEINS; NEURONS; NOREPINEPHRINE; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PITUITARY-ADRENAL SYSTEM; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, WISTAR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SIGNAL TRANSDUCTION; SOLITARY NUCLEUS; SUBSTANCE WITHDRAWAL SYNDROME; TYROSINE 3-MONOOXYGENASE;

EID: 79251484353     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01090.x     Document Type: Article

References (44)

1. Aston-Jones G, Kalivas PW, (2008). Brain norepinephrine rediscovered in addiction research. Biol Psychiatry 63: 1005-1006.
2. Bobrovskaya L, Gilligan C, Bolster EK, Flaherty JJ, Dickson PW, Dunkley PR, (2007). Sustained phosphorylation of tyrosine hydroxylase at serine 40: a novel mechanism for maintenance of catecholamine synthesis. J Neurochem 100: 479-489.
3. Contarino A, Papaleo F, (2005). The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opioid withdrawal. Proc Natl Acad Sci USA 102: 18649-18654.
4. Deak T, Nguyen KT, Ehrlich AL, Watkins LR, Spencer RL, Maier SF, et al. (1999). The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140: 79-86.
5. Delfs JM, Zhu Y, Druhan JP, Aston-Jones G, (2000). Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature 403: 430-434.
6. Dunkley PR, Bobrovskaya L, Graham ME, von Nagy-Felsobuki EI, Dickson PW, (2004). Tyrosine hydroxylase phosphorylation: regulation and consequences. J Neurochem 91: 1025-1043.
7. Frenois F, Cador M, Caille S, Stinus L, Le Moine C, (2002). Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci 16: 1377-1389.
8. Fuertes G, Laorden ML, Milanés MV, (2000). Noradrenergic and dopaminergic activity in the hypothalamic paraventricular nucleus after naloxone-induced morphine withdrawal. Neuroendocrinology 71: 60-67.
9. Gold LH, Stinus L, Inturrisi CE, Koob GF, (1994). Prolonged tolerance, dependence and abstinence following subcutaneous morphine pellets implantation in the rat. Eur J Pharmacol 253: 45-51.
10. Grakalic I, Schindler C, Baumann M, Rice K, Riley A, (2006). Effects of stress modulation on morphine-induced conditioned place preferences and plasma corticosterone levels in Fischer, Lewis, and Sprague-Dawley rat strains. Psychopharmacology 189: 277-286.
11. Hauger RL, Risbrough V, Brauns O, Dautzenberg FM, (2006). Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets 5: 453-479.
12. 40. Neurochem Res 18: 15-26.
13. Houshyar H, Manalo S, Dallman MF, (2004). Time-dependent alterations in mRNA expression of brain neuropeptides regulating energy balance and hypothalamo-pituitary-adrenal activity after withdrawal from intermittent morphine treatment. J Neurosci 24: 9414-9424.
14. Iredale PA, Alvaro JD, Lee Y, Terwilliger R, Chen YL, Duman RS, (2000). Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J Neurochem 74: 199-208.
15. Kageyama K, Li C, Vale WW, (2003). Corticotropin-releasing factor receptor type 2 messenger ribonucleic acid in rat pituitary: localization and regulation by immune challenge, restraint stress, and glucocorticoids. Endocrinology 144: 1524-1532.
16. Koob GF, (1999). Stress, corticotropin-releasing factor, and drug addiction. Ann N Y Acad Sci 897: 27-45.
17. Koob GF, (2008). A role for brain stress system in addiction. Neuron 59: 11-34.
18. Koob G, Kreek MJ, (2007). Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry 164: 1149-1159.
19. Kumer SC, Vrana KE, (1996). Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 67: 443-462.
20. 2-adrenoceptors. J Pharmacol Exp Ther 293: 578-584.
21. Laorden ML, Castells MT, Milanés MV, (2002a). Effects of morphine and morphine withdrawal on brainstem neurons innervating hypothalamic nuclei that control the pituitary-adrenocortical axis in rats. Br J Pharmacol 136: 67-75.
22. Laorden ML, NÃñez C, Almela P, Milanés MV, (2002b). Morphine withdrawal-induced c-fos expression in the hypothalamic paraventricular nucleus is dependent on the activation of catecholaminergic neurones. J Neurochem 83: 132-140.
23. Lu L, Liu D, Ceng X, Ma L, (2000). Differential role of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci 12: 4398-4404.
24. Maldonado R, (1997). Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci Biobehav Rev 1: 91-104.
25. Maldonado R, Blendy JA, Tzavara E, Gass P, Roques BP, Haoune J, et al. (1996). Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. Science 273: 657-659.
26. Marcinkiewcz CA, Prado MM, Isaac SK, Marshall A, Rylkova D, Bruijnzeel AW, (2009). Corticotropin-releasing factor within the central nucleus of the amygdala and the nucleus accumbens shell mediates the negative affective state of nicotine withdrawal in rats. Neuropsychopharmacology 34: 1743-1752.
27. Maruyama H, Makino S, Noguchi T, Nishioka T, (2007). Central type 2 corticotropin-releasing hormone receptor mediates hypothalamic-pituitary- adrenocortical axis activation in the rat. Neuroendocrinology 86: 1-16.
28. 1) antagonists on the brain stress system responses to morphine withdrawal. Mol Pharmacol 77: 864-873.
29. NÃñez C, Foldes A, Laorden ML, Milanes MV, Kovács KJ, (2007a). Activation of stress-related hypothalamic neuropeptide gene expression during morphine withdrawal. J Neurochem 101: 1060-1071.
30. 2 cell group. Role of ERK1/2. Endocrinology 148: 5780-5793.
31. NÃñez C, Földes A, Pérez-Flores D, García-Borrõn JC, Laorden ML, Kovács KJ, et al. (2009). Elevated glucocorticoid levels are responsible for induction of tyrosine hydroxylase (TH) mRNA expression, phosphorylation and enzyme activity in the nucleus of the solitary tract (NTS-A2) during morphine withdrawal. Endocrinology 150: 3118-3127.
32. Owens MJ, Nemeroff CB, (1991). Physiology and pharmacology of corticotropin releasing factor. Pharmacol Rev 43: 425-473.
33. Palkovits M, (1973). Isolated removal of hypothalamic or other brain nuclei of the rat. Brain Res 59: 449-450.
34. Papaleo F, Kitchener P, Contarino A, (2007). Disruption of the CRF/CRF(1) receptor stress system exacerbates the somatic signs of opiate withdrawal. Neuron 53: 577-589.
35. 2 receptor pathway decreases the somatic expression of opiate withdrawal. Neuropsychopharmacology 33: 2878-2887.
36. Paxinos G, Watson C, (2007). The Rat Brain in Stereotaxic Coordinates. Academic Press: Amsterdam.
37. Rühmann A, Bonk I, Lin CR, Rosenfeld MG, Spiess J, (1998). Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci USA 95: 15264-15269.
38. Sinha R, (2007). The role of stress in addiction relapse. Curr Psych Report 9: 388-395.
39. Sinha R, (2008). Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci 1141: 105-130.
40. Smith RJ, Aston-Jones G, (2008). Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence. Brain Struct Funct 213: 43-61.
41. 1 antagonists block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 30: 90-98.
42. Tilders FJ, Berkenbosch F, Vermes I, Linton EA, Smelek PG, (1985). Role of epinephrine and vasopressin in the control of the pituitary-adrenal response to stress. Fed Proc 44: 155-168.
43. Valdez GR, Sabino V, Koob GF, (2004). Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation. Alcohol Clin Exp Res 28: 865-872.
44. Van Pett K, Viau V, Bittencourt JC, Li HY, Arias C, Prins GS, et al. (2000). Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428: 191-212.